CFRA sets a price target of $126 for Novartis, indicating a potential increase of about 2.16%.Zacks Investment Research identifies Novartis as a top value stock for long-term investment, highlighting its strong market position.Novartis's current stock price is $123.12, with a market capitalization of approximately $240.22 billion.Novartis (NYSE:NVS) is a global healthcare company based in Switzerland, known for its innovative medicines and treatments. It operates in various segments, including pharmaceutica ...

CFRA maintains a "Hold" rating for Novartis (NYSE:NVS) with a price target of $126, indicating stability in its stock value.Zacks Investment Research identifies Novartis as a top value stock, highlighting its potential for long-term investment success.With a market capitalization of approximately $241.14 billion and a slight increase in stock price, Novartis demonstrates solid fundamentals and a strong market position.Novartis (NYSE:NVS) is a global healthcare company based in Switzerland, known for its inn ...

Wall Street expects earnings per share (EPS) of $2.26, with analysts projecting a slightly higher EPS of $2.28.Revenue forecast is approximately $13.87 billion, closely followed by analysts' estimates of $13.7 billion.Novartis showcases a price-to-earnings (P/E) ratio of 18.99 and a beta of 0.64, indicating moderate volatility.Novartis AG, listed on the NYSE:NVS, is a global healthcare company known for its innovative medicines and treatments. The company is a major player in the pharmaceutical industry, co ...